


ABSTRACT OF THE DISCLOSURE

5 The invention relates to the use of novel cyclohexyl analogues of E-type prostaglandins as EP<sub>4</sub> agonists, in general, and, in particular as ocular hypotensives. The cyclohexyl analogues used in accordance with the invention are represented by the following formula I:



10

wherein the wavy segments represent  $\alpha$  or  $\beta$  bond, dashed line represents the presence or absence of a bond W, Y, Z, R, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined in the specification.